Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDV/SOF effect on TAF PK in HIV
NCT03126370Phase 4Completed
- Sponsor
- University of Colorado Denver
- Start
- Jan 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of Colorado Denver. Primary endpoints: Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours for Tenofovir and Tenofovir-diphosphate in Peripheral Blood Mononuclear Cells at 28 weeks. Started Jan 2018; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03126370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126370.